MHRA: 14-Day Pilot Programme Speeds Up Phase 1 Clinical Trials in UK

• The MHRA has launched a 14-day pilot programme to speed up regulatory assessment of Phase 1 clinical trials.
• The initiative aims to deliver the first wave 1 regulatory assessment in 14 calendar days by the end of 2026.
• The accelerated pathway is expected to reduce approval times and make the UK more attractive for clinical trial sponsors.

By piloting a two-week assessment timeline for suitable trials, the MHRA seeks to boost the UK's competitiveness in early-phase research and encourage sponsors to run more Phase 1 studies in the UK.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has launched a 14-day pilot programme to speed up the regulatory assessment of Phase 1 clinical trials. This initiative is aimed at delivering the first wave 1 regulatory assessment in 14 calendar days for qualifying applications by the end of 2026.

The pilot programme is part of the MHRA's efforts to boost the UK's competitiveness in early-phase research and encourage sponsors to run more Phase 1 studies in the country. By piloting a two-week assessment timeline for suitable trials, the MHRA seeks to reduce the regulatory burden on clinical trial sponsors.

The pilot programme is an accelerated pathway introduced in response to stakeholder and government calls for faster clinical trial start-ups. The MHRA has used a controlled, evidence-based approach to maintain high safety and quality standards while streamlining the regulatory process.

This move reflects the UK's efforts to position itself as a hub for life sciences research and development. The accelerated pathway is expected to reduce the time it takes for sponsors to receive regulatory approval for Phase 1 trials, making the UK a more attractive location for clinical trial sponsors.

The potential impact of this pilot programme on the timelines for starting Phase 1 clinical trials in the UK should be closely watched by lawyers and compliance officers. The streamlined regulatory process could reduce approval times, making it easier for sponsors to initiate trials.

As the UK continues to navigate its post-Brexit regulatory landscape, initiatives like this pilot programme demonstrate the government's commitment to supporting the life sciences sector. By reducing bureaucratic hurdles, the MHRA aims to make the UK a more competitive destination for clinical trial research.

Lawyers and compliance officers should watch for the potential impact on their clients' timelines for starting Phase 1 clinical trials in the UK, as this pilot programme could streamline the regulatory process and reduce approval times.

Source: Original reporting via GOV.UK